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get for high-value care through standardization of practice. At our institution, we assessed utilization patterns of CRRT and established evidence-based guidelines to standardize process flow and promote meaningful use.
Methods | A multidisciplinary task force was organized in
October 2015 to assess CRRT utilization patterns. Interventions were implemented throughout fiscal year (FY) 2016, including the creation of evidence-based guidelines that: (1) clarified each physician's role in the initiation, maintenance, and cessation of CRRT; (2) defined indications to start therapy with a focus on patient goals of care; (3) described situations where CRRT would be medically inappropriate; (4) mandated daily cross-disciplinary communication between medical teams and key stakeholders; and (5) provided guidance on discontinuing CRRT. Additional measures to minimize excess laboratory tests and promote awareness of CRRT were also implemented. Comparisons between preintervention (FY 2014 -2015 and postintervention (FY 2016 (FY -2017 The mean duration of CRRT decreased by 11.3% from the preintervention period to the postintervention period (7.43 vs 6.59 days; P = .03). Similarly, the average direct cost of CRRT decreased by 9.8% ($11 642 vs $10 506; P < .001). This led to a savings of $1136 per patient, or an estimated annual savings of $481 664 after the intervention.
Discharge disposition of patients on CRRT changed from the preintervention period to the postintervention period (Table) . The proportion of patients expiring on CRRT decreased from 60.3% to 47.5%, while the proportion of patients transitioning to comfort care increased from 3% to 8.6% (P < .001).
Discharge disposition of patients on CRRT also varied by age. Compared with patients ages 18 to 45 years, those over the age of 80 years had the highest mortality rate (63.9% vs 43.8%), and the lowest rate of discharge to home (4.6% vs 34.2%; P < .001).
Discussion | Our institution targeted high-value care in CRRT with a series of interventions that standardized its process flow. These interventions included a set of evidence-based guidelines that established physician roles, mandated daily cross-disciplinary communication, encouraged appropriate patient selection for therapy, and emphasized patient goals of care. While the volume of patients and total number of CRRT days continued to grow after our intervention in FY 2016, we decreased the average duration of treatment from 7.43 days to 6.59 days per patient, and decreased the average direct cost 
Intervention Intervention
While the number of patients on CRRT increased over time, the mean duration of CRRT decreased by 11.3% from the preintervention period to the postintervention period (7.43 vs 6.59 days; P = .03). The average direct cost of CRRT decreased by 9.8% ($11 642 vs $10 506; P < .001). CRRT indicates continuous renal replacement therapy; FY, fiscal year.
Letters of CRRT from $11 642 to $10 506. Furthermore, the interventions were associated with metrics of appropriate use, including a decrease in the proportion of patients who died while on CRRT, and an increase in the proportion of patients transitioning to comfort care. These results reflect our institution's goal to facilitate meaningful use of continuous dialysis in our intensive care units. 
COMMENT & RESPONSE

Evidence-Based Rationale for Use of Inferior Vena Cava Filters
To the Editor Inferior vena cava (IVC) filters are used to prevent deep vein thromboses from becoming pulmonary emboli (PE).
In an Editor's Note in a recent issue of JAMA Internal Medicine, Dr Redberg argues that the absence of evidence of benefit and the definite harms of IVC filters warrants a moratorium on their use. 1 This is a step away from evidence-based medicine. Admittedly, there is limited evidence of benefit, but what evidence exists is scientifically sound; the PREPIC prospective randomized study 2 8-year data clearly showed a 50% decrease in PE risk after IVC filter placement. On the other hand, there are no large IVC filter studies that support the claim of an increase in clinically significant negative outcomes. The claim of harm is based on case reports; the documented incidence of clinically significant filter-related complications is similar to the risk of complication from the wellaccepted alternative of anticoagulation.
3,4 Analysis of the 10 serious complications attributed to filter placement by Sarosiek and colleagues, 5 yielded a 1.1% incidence; this is well below the reported hemorrhagic complication rates attributable to anticoagulation.
4
The widespread claim of an increased incidence of deep vein thrombosis is flawed because the overall venous thromboembolism (VTE) recurrence rates are similar for patients with or without filters.
2 The 7.8% VTE rate after filter placement reported by Sarosiek and colleagues 5 falls within the 4% to 9% VTE rates reported for patients treated with the gold standard of anticoagulation.
2,5
The use of IVC filters has expanded beyond evidencebased benefits, and there is a good argument that use should 
